RBC Capital maintains Bausch Health stock rating ahead of Q3 results
RBC Capital reiterated a Sector Perform rating on Bausch Health (BHC) with a $9.00 price target, citing undervaluation. The firm projects Q3 2026 revenue of $2.79B and adjusted EBITDA of $1.037B. BHC stock has gained 7.3% in the past week. The company will report Q3 results on October 28, with key focus areas including patent litigation and margin durability.
How this was made
The 30-second read
Why it matters
The analyst's reaffirmed rating and higher price target could attract buying interest, especially given the stock's recent 7.3% weekly gain.
Market read
Analyst coverage ahead of earnings can move the stock; investors may adjust positions before the Oct 28 report.
What to watch
Potential headwinds from pending patent litigation and generic competition could temper gains.
Background
RBC Capital provides a rating and price target for BHC ahead of its Q3 earnings release on Oct 28.
Ticker impact
RBC Capital reiterated a Sector Perform rating on Bausch Health (BHC) with a $9 price target and forecast Q3 revenue, providing fresh analyst coverage.
likely upward pressure as investors price in the higher target and favorable Q3 outlook
The new rating and $9 target are above the current $6.15 price, indicating a bullish bias.
Market effects
Positive sentiment may spill over to the broader healthcare sector.
North American healthcare stocks could see modest gains.
Limited to investors tracking US-listed pharma stocks.
Counterpoint
The rating maintenance may already be priced in, limiting upside.
Key entities
- AnalystRBC Capital
Equity research firm issuing the rating.
- CompanyBausch Health Companies
US-listed healthcare firm (NYSE:BHC).
